Associated Papers
Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations.
Varadarajan K et al.
Molecular Cancer Therapeutics, 2025
40300249 (PubMed )
Supplement: mct-24-0884_supplementary_table_3_suppst3.pdf
A novel frameshift mutation in Phosphoinositide 3-kinase regulatory subunit 1 (PIK3R1) causes immunodeficiency and Amyotrophic Lateral Sclerosis (ALS).
Calco B et al.
Biorxiv : the Preprint Server for Biology, 2025
Pan-cancer analyses identify oncogenic drivers, expression signatures, and therapeutic vulnerabilities in RHO GTPase pathway genes.
Fernández R et al.
Frontiers in Bioinformatics, 2025
Select a paper to view details